Anilides of (<i>R</i>)-Trifluoro-2-hydroxy-2-methylpropionic Acid as Inhibitors of Pyruvate Dehydrogenase Kinase
作者:Gregory R. Bebernitz、Thomas D. Aicher、James L. Stanton、Jiaping Gao、Suraj S. Shetty、Douglas C. Knorr、Robert J. Strohschein、Jennifer Tan、Leonard J. Brand、Charles Liu、Wei H. Wang、Christine C. Vinluan、Emma L. Kaplan、Carol J. Dragland、Dominick DelGrande、Amin Islam、Robert J. Lozito、Xilin Liu、Wieslawa M. Maniara、William R. Mann
DOI:10.1021/jm0000923
日期:2000.6.1
The optimization of a series of anilide derivatives of (R)-3,3, 3-trifluoro-2-hydroxy-2-methylpropionic acid as inhibitors of pyruvate dehydrogenase kinase (PDHK) is described that started from N-phenyl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide 1 (IC(50) = 35 +/- 1.4 microM). It was found that small electron-withdrawing groups on the ortho position of the anilide, i.e., chloro, acetyl, or bromo
描述了从N-苯基-3,3开始优化一系列作为丙酮酸脱氢酶激酶(PDHK)抑制剂的(R)-3,3,3-三氟-2-羟基-2-甲基丙酸的苯胺衍生物,3-三氟-2-羟基-2-甲基丙酰胺1(IC(50)= 35 +/- 1.4 microM)。已经发现,在苯胺的邻位上的小的吸电子基团,即氯,乙酰基或溴,增加了20-40倍的效力。当苯胺在4位被吸电子基团(即羧基,羧酰胺和亚磺酰胺)取代时,该系列化合物的口服生物利用度最佳(通过AUC测定)。N-(2-氯-4-异丁基氨磺酰基苯基)-(R)-3,3,3-三氟-2-羟基-2-甲基丙酰胺(10a)在主酶分析中抑制PDHK,IC(50)为13 + /-1.5 nM,增强人成纤维细胞中[[14] C]乳酸盐氧化成(14)CO(2)的活性,口服剂量低至30 micromol / kg后2.5和5 h显着降低血液乳酸水平,并增加肌肉,肾脏,肝脏和心脏组织中的PDH。但是